Australia markets open in 3 hours 8 minutes

Starpharma Holdings Limited (SPL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
1.5800+0.0800 (+5.33%)
At close: 4:10PM AEST
Full screen
Previous close1.5000
Open1.5050
Bid1.5700 x 334700
Ask1.6000 x 1317400
Day's range1.5000 - 1.6100
52-week range1.0150 - 2.5200
Volume686,649
Avg. volume628,665
Market cap641.603M
Beta (5Y monthly)1.30
PE ratio (TTM)N/A
EPS (TTM)-0.0510
Earnings date24 Aug 2021 - 30 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend date25 Mar 1988
1y target est1.44
  • Starpharma to Webcast Live at Life Sciences Investor Forum June 24th
    GlobeNewswire

    Starpharma to Webcast Live at Life Sciences Investor Forum June 24th

    Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comMELBOURNE, Australia, June 24, 2021 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, OTCQX: SPHRY), based in Melbourne, Australia, today announced that Dr. Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInvestorForum.com on June 24th. DATE: Thursday, June 24th TIME: 2:30 PM ETLINK: https

  • Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021
    GlobeNewswire

    Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021

    Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.comNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. Individual investors, institutional i

  • Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants
    PR Newswire

    Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

    New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus.